Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Toxicology and Applied Pharmacology

• Publication date

  1997-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1006/TAAP.1997.8225PMID 9299600
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity.

  1997cited by this paper
• P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.

  1996cited by this paper
• Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.

  1996cited by this paper
• What have we learnt thus far from mice with disrupted P-glycoprotein genes?

  1996cited by this paper
• Substantial excretion of digoxin via the intestinal mucosa and prevention of long‐term digoxin accumulation in the brain by the mdrla P‐glycoprotein

  1996cited by this paper
• Multidrug resistance and the role of P-glycoprotein knockout mice.

  1995cited by this paper
• Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

  1995cited by this paper
• Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

  1995cited by this paper
• Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

  1994cited by this paper
• Phosphatidylcholine translocase: a physiological role for the mdr2 gene.

  1994cited by this paper
• Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals.

  1993cited by this paper
• Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.

  1993cited by this paper
• The chemistry and pharmacology of avermectins.

  1992cited by this paper
• mdr2 encodes P-glycoprotein expressed in the bile canalicular membrane as determined by isoform-specific antibodies.

  1992cited by this paper
• Differential recognition of mdr1a and mdr1b gene products in multidrug resistant mouse tumour cell lines by different monoclonal antibodies.

  1992cited by this paper
• Structural analysis of the mouse mdr1a (P-glycoprotein) promoter reveals the basis for differential transcript heterogeneity in multidrug-resistant J774.2 cells

  1990cited by this paper
• Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas

  1990cited by this paper
• Physical mapping, amplification, and overexpression of the mouse mdr gene family in multidrug-resistant cells

  1990cited by this paper
• Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies.

  1990cited by this paper
• Mammalian multidrug-resistance gene: correlation of exon organization with structural domains and duplication of an ancestral gene.

  1989cited by this paper
• Ivermectin and Abamectin

  1989cited by this paper
• P‐glycoproteins encoded by mdr 1b in murine gravid uterus and multidrug resistant tumor cell lines are differentially glycosylated

  1989cited by this paper
• The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues

  1989cited by this paper
• The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus.

  1988cited by this paper
• Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines

  1985cited by this paper

• [11C]metoclopramide is a sensitive radiotracer to measure moderate decreases in P-glycoprotein function at the blood-brain barrier

  2023cites this paper
• Acute toxicity events of ivermectin in chicks’ model

  2022cites this paper
• Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects

  2021cites this paper
• First Sequencing of Caprine Mdr1 (Abcb1) mRNA Due to Suspected Neurological Adverse Drug Reaction in a Thuringian Goat Following Extra-Label Use of Doramectin

  2021cites this paper
• Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?

  2021cites this paper
• ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?

  2021cites this paper
• Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects

  2020cites this paper
• Dysfunctional MDR-1 disrupts mitochondrial homeostasis in the oocyte and ovary

  2019cites this paper
• Toxicokinetics and Drug Disposition

  2018cites this paper
• Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants

  2018cites this paper
• Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo

  2018cites this paper
• Influence of Multidrug Resistance-Associated Proteins on the Excretion of the ABCC1 Imaging Probe 6-Bromo-7-[11C]Methylpurine in Mice

  2018cites this paper
• Engineering of Two-Color ATP-Binding Cassette Biosensor Proteins for Discovery of Novel Substrates and Modulators

  2018influential citation
• The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.

  2018cites this paper
• The role of drug efflux systems in anthelmintic resistance in parasitic nematodes

  2017cites this paper
• Obstacles to Brain Tumor Therapy: Key ABC Transporters

  2017cites this paper
• 15 Encephalitis Due to Loa loa

  2017cites this paper
• Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design.

  2016cites this paper
• Genetic background ofmice strongly influences treatment resistance in the 6 Hz seizuremodel

  2015cites this paper
• Examining the selectivity in the impact of pulmonary P-gp upon the absorption of its substrates using an IPML model with knockout mice

  2015cites this paper
• Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model

  2015cites this paper
• Factors Governing P-Glycoprotein-Mediated Drug–Drug Interactions at the Blood–Brain Barrier Measured with Positron Emission Tomography

  2015cites this paper
• Loa loa Pathogenesis in Humans

  2015cites this paper
• A novel mutation in the thyroglobulin gene that causes goiter and dwarfism in Wistar Hannover GALAS rats.

  2014cites this paper
• Experimental Models to Study Pharmacoresistance in Epilepsy

  2013cites this paper
• Challenges of Using In Vitro Data for Modeling P-Glycoprotein Efflux in the Blood-Brain Barrier

  2013cites this paper
• Transporter study methodologies

  2013cites this paper
• Multidrug Resistance in Cancer: A Tale of ABC Drug Transporters

  2013cites this paper
• Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

  2013cites this paper
• Moxidectin has a lower neurotoxic potential but comparable brain penetration in P-glycoprotein-deficient CF-1 mice compared to ivermectin.

  2013influential citation
• Macrocyclic lactones in the treatment and control of parasitism in small companion animals.

  2012cites this paper
• Treatment of MDR1 Mutant Dogs with Macrocyclic Lactones

  2012cites this paper
• The importance of efflux transporters in CNS exposure to avermectin insecticides

  2012cites this paper
• Managing Mouse Fur Mites at Emory

  2012cites this paper
• Pharmacokinetic features of the antiparasitic macrocyclic lactones.

  2012cites this paper
• Charakterisierung der genetischen Epilepsie beim Australian Shepherd

  2012cites this paper
• Toxicity in animals: target species.

  2012cites this paper
• Drug-Cytokine Interactions

  2011cites this paper
• Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells

  2011cites this paper
• Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance.

  2011cites this paper
• Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

  2011cites this paper
• The effect of the dynamic interplay of P-glycoprotein and cytochrome P450 3A on the portal bioavailability of dual substrates

  2011cites this paper
• Encephalitis Due to Loa loa

  2011cites this paper
• Chapter 97 – The Role of P-glycoprotein in Preventing Developmental and Neurotoxicity: Avermectins – A Case Study

  2010cites this paper
• Comparative and veterinary pharmacogenomics.

  2010cites this paper
• Evaluation of drug transporter interactions in drug discovery and development.

  2010cites this paper
• Effects of avermectins on neurite outgrowth in differentiating mouse neuroblastoma N2a cells.

  2010cites this paper
• Seguridad de la ivermectina: toxicidad y reacciones adversas en diversas especies de mamíferos

  2010cites this paper
• Genetic Polymorphism and Susceptibility to Pesticides

  2010cites this paper
• Update information on drug metabolism systems--2009, part I.

  2010cites this paper
• The Role of P-glycoprotein in Preventing Developmental and Neurotoxicity

  2010cites this paper
• Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics.

  2010cites this paper
• Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation

  2010cites this paper
• Seguridad de la ivermectina: toxicidad y reacciones adversas en diversas especies de mamíferos Safety of ivermectin: toxicity and adverse reactions in several mammal species

  2010cites this paper
• Drug transporters: Gatekeepers controlling access of xenobiotics to the cellular interior

  2009cites this paper
• A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.

  2009cites this paper
• Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.

  2009cites this paper
• Moxidectin toxicity in senescence-accelerated prone and resistant mice.

  2009cites this paper
• In vitro-in vivo correlation in P-glycoprotein mediated transport in intestinal absorption.

  2009cites this paper
• Curcumin Inhibits the Activity of ABCG2/BCRP1, a Multidrug Resistance-Linked ABC Drug Transporter in Mice

  2009cites this paper
• Liver transporters in hepatic drug disposition: an update.

  2009cites this paper
• Parametric and non-parametric approaches to quantitating pharmacodynamic response

  2008cites this paper
• PRECLINICAL STUDY: Disposition of Δ9 tetrahydrocannabinol in CF1 mice deficient in mdr1a P‐glycoprotein

  2008cites this paper
• Relationship between drugs and functional activity of various mammalian P-glycoproteins (ABCB1).

  2008cites this paper
• In Vivo β-Secretase 1 Inhibition Leads to Brain Aβ Lowering and Increased α-Secretase Processing of Amyloid Precursor Protein without Effect on Neuregulin-1

  2008cites this paper
• In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.

  2008cites this paper
• The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 3, 1984–2008

  2008cites this paper
• Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.

  2008cites this paper
• The pharmacogenomics of P-glycoprotein and its role in veterinary medicine.

  2008cites this paper
• Senescence-Accelerated Mouse (SAM) strains have a spontaneous mutation in the Abcb1a gene.

  2008cites this paper
• Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.

  2008cites this paper
• A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain

  2008cites this paper
• Equilibrative and Concentrative Transport Mechanisms

  2007cites this paper
• Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans

  2007influential citation
• Minocycline and riluzole brain disposition: interactions with p‐glycoprotein at the blood–brain barrier

  2007cites this paper
• Function-Altering SNPs in the Human Multidrug Transporter Gene ABCB1 Identified Using a Saccharomyces-Based Assay

  2007cites this paper
• P-glycoprotein-Mediated Active Efflux of the Anti-HIV1 Nucleoside Abacavir Limits Cellular Accumulation and Brain Distribution

  2007cites this paper
• Avaliação da toxicidade de avermectinas em bovinos com idade inferior a trinta dias

  2007cites this paper
• Implications of genetic polymorphisms in drug transporters for pharmacotherapy.

  2006cites this paper
• Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse.

  2006cites this paper
• Early Preclinical Evaluation of Brain Exposure in Support of Hit Identification and Lead Optimization

  2006cites this paper
• Efavirenz Does Not Interact with the ABCB1 Transporter at the Blood—Brain Barrier

  2006cites this paper
• Breast Cancer Resistance Protein (BCRP/ABCG2) is a Major Determinant of Sulfasalazine Absorption and Elimination in the Mouse

  2006cites this paper
• THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL

  2005cites this paper
• Life and Times in Biochemical Toxicology

  2005cites this paper
• Veterinary pharmacovigilance. Part 6. Predictability of adverse reactions in animals from laboratory toxicology studies.

  2005cites this paper
• Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.

  2005cites this paper
• Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood–brain barrier of Abcb1a gene knockout mice

  2004cites this paper
• Protein Model for pollutant uptake and elimination by living organisms and its implications for ecotoxicology.

  2004cites this paper
• Gene–Environment Interactions: A Review of Effects on Reproduction and Development

  2004cites this paper
• ABC transporters and the blood-brain barrier.

  2004cites this paper
• Veterinary anthelmintics: old and new.

  2004cites this paper
• The toxicity of particular veterinary drug residues.

  2004cites this paper
• Use of Loperamide as a Phenotypic Probe of mdr1a Status in CF-1 Mice

  2004cites this paper
• Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.

  2004cites this paper
• Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon

  2003cites this paper
• The presence of xenobiotic transporters in rat placenta.

  2003cites this paper
• Role of P-Glycoprotein in Pharmacokinetics

  2003cites this paper
• Ivermectin: does P-glycoprotein play a role in neurotoxicity?

  2003cites this paper
• Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein.

  2003influential citation